Enhancers of particulate guanylyl cyclase receptor a
AssigneesMayo Foundation for Medical Education and Research, University of Florida Research Foundation, Inc.
InventorsJohn C. Burnett, Jr., Sasantha J. Sangaralingham, Siobhan Malany, Satyamaheshwar Peddibhotla
Life of this patent
Estimating the term…
Abstract
In some embodiments, the present disclosure provides a compound(S) or (R)-N-(4.6-difluorobenzo[d]thiazol-2-yl)-1-(2-(dimethylamino)ethyl) piperidine-3-carboxamide, as described herein, or a pharmaceutically acceptable salt thereof. Pharmaceutical compositions comprising the compound, and methods of treating. e.g., metabolic diseases using the compound are also provided.
Claims14
A compound(S)-N-(4,6-difluorobenzo[d]thiazol-2-yl)-1-(2-(dimethylamino)ethyl) piperidine-3-carboxamide having formula:
- or a pharmaceutically acceptable salt thereof.
A compound (R)-N-(4,6-difluorobenzo[d]thiazol-2-yl)-1-(2-(dimethylamino)ethyl) piperidine-3-carboxamide having formula:
- or a pharmaceutically acceptable salt thereof.
A pharmaceutical composition comprising a compound or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, wherein said compound is:
- (a) (S)-N-(4,6-difluorobenzo[d]thiazol-2-yl)-1-(2-(dimethylamino)ethyl) piperidine-3-carboxamide having formula:
- or
- (b) (R)-N-(4,6-difluorobenzo[d]thiazol-2-yl)-1-(2-(dimethylamino)ethyl) piperidine-3-carboxamide having formula:
A method of modulating particulate guanylyl cyclase receptor A (pGC-A) in a cell, the method comprising contacting the cell with an effective amount of a compound or a pharmaceutically acceptable salt thereof, wherein said compound is:
- (a) (S)-N-(4,6-difluorobenzo[d]thiazol-2-yl)-1-(2-(dimethylamino)ethyl) piperidine-3-carboxamide having formula:
- or
- (b) (R)-N-(4.6-difluorobenzo[d]thiazol-2-yl)-1-(2-(dimethylamino)ethyl) piperidine-3-carboxamide having formula:
Dependencies are inferred from the claim text.